

Technology Appraisal Committee A Interests Register

Topic: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

Publication Date: 16 July 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Patrick de Barr	TAC Committee Member	Direct- financial	Patrick has received paid employment in the past from Sanofi - working in an unrelated disease area. He declares no ongoing financial or personal interest.	11/04/2025	It was agreed that Patrick's declaration would not prevent him from participating in discussions on this appraisal
Neil Wright	Clinical Expert	Direct - financial	<p>Neil has received payment for attending Advisory boards regarding Teplizumab hosted by Sanofi.</p> <ul style="list-style-type: none"> - May 2024 – Virtual Advisory board £1615. - July 2024 Advisory Board F2F £1615. <p>He has previously attended Advisory boards hosted by Provention-Bio regarding Teplizumab</p>	06/05/2025	It was agreed that Neil's declaration would not prevent him from acting as an expert on this appraisal
Neil Wright	Clinical Expert	Direct – non financial	Neil has received sponsorship support to attend the 2024 ISPAD		It was agreed that Neil's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			meeting in Lisbon (Flight, Accommodation & Registration)		prevent him from acting as an expert on this appraisal
Neil Wright	Clinical Expert	Indirect	Having run the PROTECT study of Teplizumab in newly diagnosed type 1 Diabetes (stage 3 Diabetes) and in running the PROTECT extension study as these are commercial studies on the NIHR portfolio Sheffield Childrens' NHS Trust, by whom Neil is employed, he has received research income in relation to these studies.		It was agreed that Neil's declaration would not prevent him from acting as an expert on this appraisal.